Update shared on08 Aug 2025
With no significant changes in Exosens' discount rate or future P/E, the consensus analyst price target remained steady at €42.57.
What's in the News
- Exosens announces a share repurchase program for up to 240,000 shares, with repurchased shares to be used for employee performance share plans and offer expiring on October 31, 2025.
- The Board of Directors authorizes a buyback plan.
- The company provides earnings guidance for 2025-2026, projecting continuing strong performance with revenue growth in the high teens.
Valuation Changes
Summary of Valuation Changes for Exosens
- The Consensus Analyst Price Target remained effectively unchanged, at €42.57.
- The Discount Rate for Exosens remained effectively unchanged, at 7.20%.
- The Future P/E for Exosens remained effectively unchanged, at 30.12x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.